ArticleScientific reports2025
Newborn screening for inherited metabolic disorders in central China: a retrospective study of 153,956 infants using non-derivatized tandem mass spectrometry.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Comprehensive Meta-Analytical Investigation into the Incidence of Neonatal Amino Acid Metabolic Disorders Across China.International journal of neonatal screening · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Inherited metabolic disorders (IMDs) are genetic conditions characterized by toxic metabolite accumulation or deficiencies in essential products, often leading to severe clinical symptoms. Neonatal screening using advanced methods, such as tandem mass spectrometry (MS/MS), facilitates early detection and intervention, significantly expanding the range of detectable disorders. However, IMD incidence varies considerably across and within different regions globally. This study examined the incidence, spectrum, and genetic features of IMDs detectable by the regional MS/MS screening panel in a cohort of 153,956 newborns in Changzhi, central China, over the period from May 2015 to April 2020. MS/MS served as the primary screening tool, while GC/MS and next-generation sequencing (NGS) provided confirmatory analyses. Of the screened population, 129 infants received a diagnosis of IMDs, resulting in an incidence rate of 1 in 1,193 neonates. Confirmed cases comprised amino acid disorders (87 cases, 1:1,770), organic acidemias (23 cases, 1:6,694), and fatty acid oxidation disorders (18 cases, 1:8,553), with phenylalanine hydroxylase deficiency (PAHD) being the most prevalent disorder (64.4%, 1:1,855). Genetic analysis revealed particular mutations associated with specific IMDs. These findings provide region-specific epidemiological and genetic data on screened IMDs in central China, which may help inform future refinement of newborn screening panels and counselling strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.